IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin